Prognozy (mln) dla Glenmark Pharmaceuticals Limited
| Okres |
2024-03-31 |
2025-03-31 |
2026-03-31 |
2027-03-31 |
2028-03-31 |
2029-03-31 |
| Przychód (średnia) |
124,283.00 |
124,283.00 |
134,330.67 |
147,505.25 |
164,186.25 |
182,245.00 |
| Przychód Δ r/r |
0.00% |
0.00% |
8.08% |
9.81% |
11.31% |
11.00% |
| Przychód (min) |
120,636.83 |
120,636.83 |
133,547.71 |
145,457.75 |
160,616.96 |
182,244.94 |
| Przychód (max) |
127,929.17 |
127,929.17 |
135,242.07 |
149,062.93 |
168,675.09 |
182,245.06 |
| EBITDA (średnia) |
18,726.29 |
18,385.76 |
19,872.15 |
21,821.13 |
24,288.83 |
26,960.34 |
| EBIT (średnia) |
13,296.53 |
12,916.61 |
13,960.85 |
15,330.07 |
17,063.71 |
18,940.54 |
| EBIT % |
10.70% |
10.39% |
10.39% |
10.39% |
10.39% |
10.39% |
| Zysk netto (średni) |
4,706.99 |
4,743.48 |
13,975.49 |
17,362.11 |
21,547.00 |
27,554.75 |
| Zysk netto % |
3.79% |
3.82% |
10.40% |
11.77% |
13.12% |
15.12% |
| EPS (średnia) |
16.80 |
16.80 |
49.57 |
60.31 |
74.19 |
97.65 |
| Liczba analityków (Przychody) |
6 |
6 |
9 |
8 |
8 |
2 |
| Liczba analityków (EPS) |
3 |
4 |
8 |
10 |
8 |
2 |
| symbol |
GLENMARK.BO |
GLENMARK.BO |
GLENMARK.BO |
GLENMARK.BO |
GLENMARK.BO |
GLENMARK.BO |